Compare DAIO & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAIO | EVAX |
|---|---|---|
| Founded | 1969 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 25.5M |
| IPO Year | 2026 | 2020 |
| Metric | DAIO | EVAX |
|---|---|---|
| Price | $2.42 | $2.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $12.25 |
| AVG Volume (30 Days) | 27.0K | ★ 116.1K |
| Earning Date | 11-10-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $21,500,000.00 | N/A |
| Revenue This Year | $3.26 | N/A |
| Revenue Next Year | $25.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.16 | $2.72 |
| 52 Week High | $4.49 | $6.92 |
| Indicator | DAIO | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 32.51 | 42.96 |
| Support Level | $2.40 | $2.90 |
| Resistance Level | $2.76 | $3.56 |
| Average True Range (ATR) | 0.16 | 0.38 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 7.97 | 11.80 |
Data I/O Corp provides semiconductor programming, security provisioning, and intellectual property protection and management solutions used in electronics manufacturing with flash memory, microcontrollers, and flash memory-based intelligent devices as well as secure element devices, authentication devices and secure microcontrollers. It operates as a single segment entity, with the sole objective to design, manufacture, and sell programming solutions and Programming-as-a-Service (PaaS) to the world's various electronics manufacturers including OEMs, CMs and EMS companies. The company operate in three separate locations Redmond, Washington; Shanghai, China; and Munich, Germany.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.